Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent…
Biotechnology
US, Boston [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 74.26 | -18.80 | -73.02 | |
| Graham Fair Price | 9.27 | 7.36 | 6.73 | |
| PEG | -99.07 | -0.02 | 2.07 | |
| Price/Book | 159.97 | 41.68 | 16.03 | |
| Price/Cash Flow | 65.68 | -31.79 | -92.64 | |
| Prices/Earnings | 72.23 | -4.54 | -16.34 | |
| Price/Sales | -11.99 | 98.85 | 112.32 | |
| Price/FCF | 65.68 | -31.79 | -92.64 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 2.07 | 0.88 | 0.87 | |
| Operating Margin | -216.37 | -5.39 | -1.70 | |
| ROA | -336.84 | -0.55 | -0.13 | |
| ROE | -0.25 | -2.30 | -836.08 | |
| ROIC | -0.24 | -0.83 | -240.66 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 85.07 | -0.13 | 67953.97 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.06 | -2.39 | 3807.97 | |
| EPS QOQ | 0.08 | -2.36 | 2885.71 | |
| FCF QOQ | < 0.005 | -1.75 | -39233.66 | |
| Revenue QOQ | 0.08 | 0.07 | -6.98 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 240.07 | 255.38 | 6.38 | |
| Days Sales Outstanding (DSO) | 55.21 | 50.93 | -7.75 | |
| Inventory Turnover | 0.37 | 0.35 | -5.99 | |
| Debt/Capitalization | < 0.005 | 0.64 | 8548.79 | |
| Quick Ratio | 5.27 | 3.99 | -24.31 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 2.87 | 1.02 | -64.29 | |
| Cash | 4.66 | 3.35 | -28.19 | |
| Capex | < 0.005 | -0.67 | 3937891.10 | |
| Free Cash Flow | -0.50 | -1.34 | -170.54 | |
| Revenue | 0.41 | 0.43 | 5.49 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad